Econic Biosciences is developing a healthcare platform that targets extrachromosomal DNA (ecDNA), a significant driver of oncogenic gene amplification linked to treatment-resistant cancers. By utilizing artificial intelligence to identify and characterize ecDNA, the company aims to create targeted therapies that improve clinical outcomes for cancer patients.
Funding
$15.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers develop resistance to treatment due to oncogenic gene amplification driven by extrachromosomal DNA (ecDNA). This ecDNA, found in most cancer types, contributes to tumor evolution and heterogeneity, leading to poor clinical outcomes. Current cancer therapies often fail to address this underlying cause of oncogene amplification.
Solution
Econic Biosciences is developing targeted therapies that address the root cause of oncogenic dysregulation by targeting ecDNA. The company leverages mechanistic insights into ecDNA biology to identify key molecular pathways that drive ecDNA genesis, replication, segregation, and maintenance. By focusing on these pathways, Econic Biosciences aims to create cancer-specific treatments that can overcome resistance and improve outcomes for a significant portion of cancer patients. Their approach involves using computational and analytical tools to identify and validate novel therapeutic targets related to ecDNA.
Target Audience
The primary target audience includes cancer patients with tumors driven by ecDNA, as well as clinical oncologists seeking new therapeutic options for treatment-resistant cancers.
Features
- Focus on therapeutic targets related to ecDNA genesis, replication, segregation, and maintenance
- Computational and analytical tools for identifying and validating novel therapeutic targets
- Aims to develop cancer-specific therapies